#moderna
moderna
8,173 рет көрілді
62 адам талқылап жатыр
Қызу саудада
Ең соңғы
·
--
Moderna bStock Faces Fresh Test of Support 🚧
Price action – $MRNAB is trading at $255.89 on Binance Spot, down 7.74% over the past 24 hours. The candle closed near the lower edge of the recent range, hinting at a defensive stance as sellers press.
Why it matters – The biotech sector is awaiting the next wave of mRNA pipeline data, and a sustained dip could pressure broader biotech sentiment ahead of upcoming earnings season.
Key levels – Immediate support sits around $250.00, with a secondary floor near $245.00. Resistance looms at $260.00, while the mid‑range pivot is near $257.50, a zone that has acted as a bounce point in prior sessions.
Outlook – From a support‑defense perspective, buyers need to hold the $250 floor; failure could open a deeper decline toward $240. A clean hold may set the stage for a rebound toward the $260 ceiling.
#MRNAB #Moderna #BinanceSquare
Moderna bStock Faces Fresh Test of Support 🚧
Price action – $MRNAB is trading at $255.89 on Binance Spot, down 7.74% over the past 24 hours. The candle closed near the lower edge of the recent range, hinting at a defensive stance as sellers press.
Why it matters – The biotech sector is awaiting the next wave of mRNA pipeline data, and a sustained dip could pressure broader biotech sentiment ahead of upcoming earnings season.
Key levels – Immediate support sits around $250.00, with a secondary floor near $245.00. Resistance looms at $260.00, while the mid‑range pivot is near $257.50, a zone that has acted as a bounce point in prior sessions.
Outlook – From a support‑defense perspective, buyers need to hold the $250 floor; failure could open a deeper decline toward $240. A clean hold may set the stage for a rebound toward the $260 ceiling.
#MRNAB #Moderna #BinanceSquare
Price action – $MRNAB is trading at $255.89 on Binance Spot, down 7.74% over the past 24 hours. The candle closed near the lower edge of the recent range, hinting at a defensive stance as sellers press.
Why it matters – The biotech sector is awaiting the next wave of mRNA pipeline data, and a sustained dip could pressure broader biotech sentiment ahead of upcoming earnings season.
Key levels – Immediate support sits around $250.00, with a secondary floor near $245.00. Resistance looms at $260.00, while the mid‑range pivot is near $257.50, a zone that has acted as a bounce point in prior sessions.
Outlook – From a support‑defense perspective, buyers need to hold the $250 floor; failure could open a deeper decline toward $240. A clean hold may set the stage for a rebound toward the $260 ceiling.
#MRNAB #Moderna #BinanceSquare
·
--
Genome Gains: $MRNAB Holds Steady on Binance Spot 🌐
Price action – $MRNAB is trading at $227.73 on Binance Spot, up 3.78 % in the past 24 h with modest volume. The rally follows a broader biotech bounce as investors price‑roll recent mRNA pipeline optimism.
Key levels – Immediate support sits near $220, the prior swing low that anchored the last pull‑back. Mid‑range equilibrium is around $227.5, acting as a pivot for current price action. The nearest resistance cluster is at $235, with a secondary ceiling near $242 should the upside gain momentum.
Outlook – Neutral. The token is likely to consolidate within the $220‑$235 range as the market digests sector‑wide data. Traders should wait for a decisive break above $235 or below $220 before committing to a directional bias.
#MRNAB #Moderna #BinanceSquare
Genome Gains: $MRNAB Holds Steady on Binance Spot 🌐
Price action – $MRNAB is trading at $227.73 on Binance Spot, up 3.78 % in the past 24 h with modest volume. The rally follows a broader biotech bounce as investors price‑roll recent mRNA pipeline optimism.
Key levels – Immediate support sits near $220, the prior swing low that anchored the last pull‑back. Mid‑range equilibrium is around $227.5, acting as a pivot for current price action. The nearest resistance cluster is at $235, with a secondary ceiling near $242 should the upside gain momentum.
Outlook – Neutral. The token is likely to consolidate within the $220‑$235 range as the market digests sector‑wide data. Traders should wait for a decisive break above $235 or below $220 before committing to a directional bias.
#MRNAB #Moderna #BinanceSquare
Price action – $MRNAB is trading at $227.73 on Binance Spot, up 3.78 % in the past 24 h with modest volume. The rally follows a broader biotech bounce as investors price‑roll recent mRNA pipeline optimism.
Key levels – Immediate support sits near $220, the prior swing low that anchored the last pull‑back. Mid‑range equilibrium is around $227.5, acting as a pivot for current price action. The nearest resistance cluster is at $235, with a secondary ceiling near $242 should the upside gain momentum.
Outlook – Neutral. The token is likely to consolidate within the $220‑$235 range as the market digests sector‑wide data. Traders should wait for a decisive break above $235 or below $220 before committing to a directional bias.
#MRNAB #Moderna #BinanceSquare
23
·
--
Vaccine Vanguard: $MRNAB Gathers Steam 🚀
Price action: $MRNAB trades at $219.78 on Binance Spot (MRNAB/USDT), slipping 0.47 % over the past 24 hours.
Why it matters: Moderna stays at the forefront of mRNA therapeutics, and fresh Q3 pipeline data could ignite broader biotech momentum.
Key levels:
- Support near $215.00, a zone that has held in prior pullbacks.
- Mid‑range equilibrium around $220.50, acting as a pivot for short‑term bias.
- Resistance at $225.00, the next hurdle before a breakout toward $230+.
Short outlook 📈: With neutral market sentiment but underlying sector strength, the dip appears buyable. The analyst angle is bullish continuation – momentum is building, and a bounce off support could set the stage for a renewed upward swing.
#MRNAB #Moderna #BinanceSquare
Vaccine Vanguard: $MRNAB Gathers Steam 🚀
Price action: $MRNAB trades at $219.78 on Binance Spot (MRNAB/USDT), slipping 0.47 % over the past 24 hours.
Why it matters: Moderna stays at the forefront of mRNA therapeutics, and fresh Q3 pipeline data could ignite broader biotech momentum.
Key levels:
- Support near $215.00, a zone that has held in prior pullbacks.
- Mid‑range equilibrium around $220.50, acting as a pivot for short‑term bias.
- Resistance at $225.00, the next hurdle before a breakout toward $230+.
Short outlook 📈: With neutral market sentiment but underlying sector strength, the dip appears buyable. The analyst angle is bullish continuation – momentum is building, and a bounce off support could set the stage for a renewed upward swing.
#MRNAB #Moderna #BinanceSquare
Price action: $MRNAB trades at $219.78 on Binance Spot (MRNAB/USDT), slipping 0.47 % over the past 24 hours.
Why it matters: Moderna stays at the forefront of mRNA therapeutics, and fresh Q3 pipeline data could ignite broader biotech momentum.
Key levels:
- Support near $215.00, a zone that has held in prior pullbacks.
- Mid‑range equilibrium around $220.50, acting as a pivot for short‑term bias.
- Resistance at $225.00, the next hurdle before a breakout toward $230+.
Short outlook 📈: With neutral market sentiment but underlying sector strength, the dip appears buyable. The analyst angle is bullish continuation – momentum is building, and a bounce off support could set the stage for a renewed upward swing.
#MRNAB #Moderna #BinanceSquare
30
·
--
🧬 $MRNAB RISES 6.42% — BIOTECH EXPOSURE IS ON THE MOVE!
Current Price: $217.67
24H Change: +6.42%
$MRNAB is showing a healthy daily gain in this market snapshot, bringing Moderna-linked tokenized stock exposure into focus.
• The current move is positive.
• Keep an eye on price stability after the rally.
• Remember that company news and wider stock-market conditions can affect performance.
Important: MRNAB is a bStock product, not a regular crypto token. Understand its structure, risks, and trading hours before taking a position.
#MRNAB #Moderna #bStocks #MarketTrends
🧬 $MRNAB RISES 6.42% — BIOTECH EXPOSURE IS ON THE MOVE!
Current Price: $217.67
24H Change: +6.42%
$MRNAB is showing a healthy daily gain in this market snapshot, bringing Moderna-linked tokenized stock exposure into focus.
• The current move is positive.
• Keep an eye on price stability after the rally.
• Remember that company news and wider stock-market conditions can affect performance.
Important: MRNAB is a bStock product, not a regular crypto token. Understand its structure, risks, and trading hours before taking a position.
#MRNAB #Moderna #bStocks #MarketTrends
Current Price: $217.67
24H Change: +6.42%
$MRNAB is showing a healthy daily gain in this market snapshot, bringing Moderna-linked tokenized stock exposure into focus.
• The current move is positive.
• Keep an eye on price stability after the rally.
• Remember that company news and wider stock-market conditions can affect performance.
Important: MRNAB is a bStock product, not a regular crypto token. Understand its structure, risks, and trading hours before taking a position.
#MRNAB #Moderna #bStocks #MarketTrends
1
54
·
--
$MRNAB IS MOVING UP — CAN BUYERS TURN A STEADY GAIN INTO A BIGGER MOVE?
Moderna bStocks ($MRNAB) has gained 4.98% over the past 24 hours. The move is more measured than some of the day's biggest gainers, giving traders a reason to watch for a structured continuation rather than chase sudden volatility.
The key is to see whether buyers can hold the entry area and push through the next price levels.
Trade Setup
• Current Price: $215.27
• Buy Zone: $211.00 – $214.00
• Entry Point: Enter only after a confirmed bounce
• TP1: $218.00
• TP2: $222.00
• TP3: $228.00
• Stop Loss: $206.50
The Next Decision
• A hold above $211 could support a move toward $218.
• A clean break above $218 may open the way toward $222.
• A drop below $206.50 invalidates the proposed setup.
$MRNAB is a tokenized stock product. Verify its relationship to the underlying Moderna share, market hours, liquidity, and product risks before trading. Do not confuse a daily gain with a guaranteed continuation.
#MRNAB #Moderna #TokenizedStocks #MarketWatch
$MRNAB IS MOVING UP — CAN BUYERS TURN A STEADY GAIN INTO A BIGGER MOVE?
Moderna bStocks ($MRNAB ) has gained 4.98% over the past 24 hours. The move is more measured than some of the day's biggest gainers, giving traders a reason to watch for a structured continuation rather than chase sudden volatility.
The key is to see whether buyers can hold the entry area and push through the next price levels.
Trade Setup
• Current Price: $215.27
• Buy Zone: $211.00 – $214.00
• Entry Point: Enter only after a confirmed bounce
• TP1: $218.00
• TP2: $222.00
• TP3: $228.00
• Stop Loss: $206.50
The Next Decision
• A hold above $211 could support a move toward $218.
• A clean break above $218 may open the way toward $222.
• A drop below $206.50 invalidates the proposed setup.
$MRNAB is a tokenized stock product. Verify its relationship to the underlying Moderna share, market hours, liquidity, and product risks before trading. Do not confuse a daily gain with a guaranteed continuation.
#MRNAB #Moderna #TokenizedStocks #MarketWatch
Moderna bStocks ($MRNAB ) has gained 4.98% over the past 24 hours. The move is more measured than some of the day's biggest gainers, giving traders a reason to watch for a structured continuation rather than chase sudden volatility.
The key is to see whether buyers can hold the entry area and push through the next price levels.
Trade Setup
• Current Price: $215.27
• Buy Zone: $211.00 – $214.00
• Entry Point: Enter only after a confirmed bounce
• TP1: $218.00
• TP2: $222.00
• TP3: $228.00
• Stop Loss: $206.50
The Next Decision
• A hold above $211 could support a move toward $218.
• A clean break above $218 may open the way toward $222.
• A drop below $206.50 invalidates the proposed setup.
$MRNAB is a tokenized stock product. Verify its relationship to the underlying Moderna share, market hours, liquidity, and product risks before trading. Do not confuse a daily gain with a guaranteed continuation.
#MRNAB #Moderna #TokenizedStocks #MarketWatch
82
·
--
Жоғары (өспелі)
$MRNA is trading at $206.06, rising 5.18%. The biotech stock is gaining attention as investors monitor developments in vaccines, medical research, and the company's future growth opportunities. Further movement will depend on market sentiment and company-specific developments.
$MRNA
{future}(MRNAUSDT)
#Write2Earn! #MRNA #Moderna #BiotechStocks
$MRNA is trading at $206.06, rising 5.18%. The biotech stock is gaining attention as investors monitor developments in vaccines, medical research, and the company's future growth opportunities. Further movement will depend on market sentiment and company-specific developments.
$MRNA
#Write2Earn! #MRNA #Moderna #BiotechStocks
$MRNA
#Write2Earn! #MRNA #Moderna #BiotechStocks
1
467
·
--
好数据出炉，股价先崩26%：Moderna癌症疫苗，医生说好，钱说不
上周四，Moderna和默克的个性化黑色素瘤疫苗晚期数据公布：1100多名患者，复发或死亡风险降42%，远处转移风险降38%。
分析师说数据“扎实”，可股价盘中一度暴跌26%，创历史最大单日跌幅，市值一度蒸发约240亿美元。
周五再跌1.25%到200.10美元，周一盘前又跌7.3%到185.45美元，盘中才抢回约198美元。
问题不在数据，在预期：今年以来这只股票涨了570%，市场要的是上次小试验的49%，不是42%。
更扎心的是估值：华尔街目标价普遍在104到138美元，高盛刚上调到137美元，Redburn直接给81美元卖出评级。
我觉得这是典型的“利好出尽”：数据不差，但570%的涨幅已经把好消息吃干了，短期就是挤泡沫，观察不追，失效位是日线收回209.59美元上方。
你觉得这是“好数据被错杀”，还是“涨太多活该跌”？
$MRNA $MRK $GS
#Moderna #美股
以上不构成投资建议，DYOR，交易有风险。
好数据出炉，股价先崩26%：Moderna癌症疫苗，医生说好，钱说不
上周四，Moderna和默克的个性化黑色素瘤疫苗晚期数据公布：1100多名患者，复发或死亡风险降42%，远处转移风险降38%。
分析师说数据“扎实”，可股价盘中一度暴跌26%，创历史最大单日跌幅，市值一度蒸发约240亿美元。
周五再跌1.25%到200.10美元，周一盘前又跌7.3%到185.45美元，盘中才抢回约198美元。
问题不在数据，在预期：今年以来这只股票涨了570%，市场要的是上次小试验的49%，不是42%。
更扎心的是估值：华尔街目标价普遍在104到138美元，高盛刚上调到137美元，Redburn直接给81美元卖出评级。
我觉得这是典型的“利好出尽”：数据不差，但570%的涨幅已经把好消息吃干了，短期就是挤泡沫，观察不追，失效位是日线收回209.59美元上方。
你觉得这是“好数据被错杀”，还是“涨太多活该跌”？
$MRNA $MRK $GS
#Moderna #美股
以上不构成投资建议，DYOR，交易有风险。
上周四，Moderna和默克的个性化黑色素瘤疫苗晚期数据公布：1100多名患者，复发或死亡风险降42%，远处转移风险降38%。
分析师说数据“扎实”，可股价盘中一度暴跌26%，创历史最大单日跌幅，市值一度蒸发约240亿美元。
周五再跌1.25%到200.10美元，周一盘前又跌7.3%到185.45美元，盘中才抢回约198美元。
问题不在数据，在预期：今年以来这只股票涨了570%，市场要的是上次小试验的49%，不是42%。
更扎心的是估值：华尔街目标价普遍在104到138美元，高盛刚上调到137美元，Redburn直接给81美元卖出评级。
我觉得这是典型的“利好出尽”：数据不差，但570%的涨幅已经把好消息吃干了，短期就是挤泡沫，观察不追，失效位是日线收回209.59美元上方。
你觉得这是“好数据被错杀”，还是“涨太多活该跌”？
$MRNA $MRK $GS
#Moderna #美股
以上不构成投资建议，DYOR，交易有风险。
319
·
--
【美股盘前异动 - Moderna $MRNAB 】
癌症疫苗三期成功了，莫德纳 $MRNA 两天跌掉四分之一。盘前 184.47 美元、跌 7.81%，距 10 月 21 日的 245.81 回撤 25%。
第一层原因在跟谁比。三期的复发或死亡风险降 42%，二期是 49%；远处转移降 38%，二期是 59%。相对降幅差了 14% 和 36%。数据是正的。比两年前那版弱。
真正卡住的是总生存。HR 0.77，区间 0.45 到 1.31，跨过 1 就等于没证明。停药率 14.0%，单用 Keytruda 是 8.7%，翻了 1.6 倍。疗效更好，代价是更多人退出。
所以卖方没否定疗效。RBC 说临床上有意义、大概率能获批，瑞银说对肾癌膀胱癌更有信心。
下调的是估值：Brookline 把 2030 年 EPS 从 19.11 砍到 18.19，Redburn 直接降到卖出。这只股年内从 29.49 涨到 200 出头，市值里很大一块押在 mRNA 治癌上。下一个变量是 ESMO 的非小细胞肺癌读数：好，这里错杀；糊，25% 只是开始。
{spot}(MRNABUSDT)
#生物科技 #moderna #币安神算子
【美股盘前异动 - Moderna $MRNAB 】
癌症疫苗三期成功了，莫德纳 $MRNA 两天跌掉四分之一。盘前 184.47 美元、跌 7.81%，距 10 月 21 日的 245.81 回撤 25%。
第一层原因在跟谁比。三期的复发或死亡风险降 42%，二期是 49%；远处转移降 38%，二期是 59%。相对降幅差了 14% 和 36%。数据是正的。比两年前那版弱。
真正卡住的是总生存。HR 0.77，区间 0.45 到 1.31，跨过 1 就等于没证明。停药率 14.0%，单用 Keytruda 是 8.7%，翻了 1.6 倍。疗效更好，代价是更多人退出。
所以卖方没否定疗效。RBC 说临床上有意义、大概率能获批，瑞银说对肾癌膀胱癌更有信心。
下调的是估值：Brookline 把 2030 年 EPS 从 19.11 砍到 18.19，Redburn 直接降到卖出。这只股年内从 29.49 涨到 200 出头，市值里很大一块押在 mRNA 治癌上。下一个变量是 ESMO 的非小细胞肺癌读数：好，这里错杀；糊，25% 只是开始。
#生物科技 #moderna #币安神算子
癌症疫苗三期成功了，莫德纳 $MRNA 两天跌掉四分之一。盘前 184.47 美元、跌 7.81%，距 10 月 21 日的 245.81 回撤 25%。
第一层原因在跟谁比。三期的复发或死亡风险降 42%，二期是 49%；远处转移降 38%，二期是 59%。相对降幅差了 14% 和 36%。数据是正的。比两年前那版弱。
真正卡住的是总生存。HR 0.77，区间 0.45 到 1.31，跨过 1 就等于没证明。停药率 14.0%，单用 Keytruda 是 8.7%，翻了 1.6 倍。疗效更好，代价是更多人退出。
所以卖方没否定疗效。RBC 说临床上有意义、大概率能获批，瑞银说对肾癌膀胱癌更有信心。
下调的是估值：Brookline 把 2030 年 EPS 从 19.11 砍到 18.19，Redburn 直接降到卖出。这只股年内从 29.49 涨到 200 出头，市值里很大一块押在 mRNA 治癌上。下一个变量是 ESMO 的非小细胞肺癌读数：好，这里错杀；糊，25% 只是开始。
#生物科技 #moderna #币安神算子
331
·
--
Төмен (кемімелі)
🚨 $MRNAB DROPS 19.21% IN 24 HOURS! 📉
{spot}(MRNABUSDT)
💰 Price: $194.41
🔴 MRNAB faces heavy selling pressure after falling sharply from recent highs. Can buyers defend $190, or will the decline continue?
📊 BOUNCE BACK OR MORE DOWNSIDE? 👀
💬 BULLISH 🟢 or BEARISH 🔴? Share your prediction!
⚠️ High volatility — manage your risk.
#MRNAB #Moderna #Crypto #Trading
🚨 $MRNAB DROPS 19.21% IN 24 HOURS! 📉
💰 Price: $194.41
🔴 MRNAB faces heavy selling pressure after falling sharply from recent highs. Can buyers defend $190, or will the decline continue?
📊 BOUNCE BACK OR MORE DOWNSIDE? 👀
💬 BULLISH 🟢 or BEARISH 🔴? Share your prediction!
⚠️ High volatility — manage your risk.
#MRNAB #Moderna #Crypto #Trading
💰 Price: $194.41
🔴 MRNAB faces heavy selling pressure after falling sharply from recent highs. Can buyers defend $190, or will the decline continue?
📊 BOUNCE BACK OR MORE DOWNSIDE? 👀
💬 BULLISH 🟢 or BEARISH 🔴? Share your prediction!
⚠️ High volatility — manage your risk.
#MRNAB #Moderna #Crypto #Trading
97
·
--
Moderna 收在242美元，华尔街平均目标价才101，股价是目标价的2.4倍，周六数据前我不追
看见了：周二 Moderna 涨6.7%，盘中243.98创52周新高。
一年前最低收盘才22.36，现在翻了10倍多；8月19日三期初步结果出来，一天涨了177%。
和默沙东合作的黑色素瘤个性化疫苗，完整三期数据10月24日22:30（北京时间）在ESMO公布。
我觉得好消息大半已经在价格里，数据只要不够惊艳，就容易见光死；过去90天公司内部人还卖了约3390万美元股票。
我怎么做：不追，也不提前做空。
数据后站稳243.98再看；跌破10月16日低点208.92，算预期打完。
周六晚数据出来前，你会拿着 Moderna 过周末吗，拿还是不拿？
$MRNA $MRK
#Moderna #癌症疫苗
Moderna 收在242美元，华尔街平均目标价才101，股价是目标价的2.4倍，周六数据前我不追
看见了：周二 Moderna 涨6.7%，盘中243.98创52周新高。
一年前最低收盘才22.36，现在翻了10倍多；8月19日三期初步结果出来，一天涨了177%。
和默沙东合作的黑色素瘤个性化疫苗，完整三期数据10月24日22:30（北京时间）在ESMO公布。
我觉得好消息大半已经在价格里，数据只要不够惊艳，就容易见光死；过去90天公司内部人还卖了约3390万美元股票。
我怎么做：不追，也不提前做空。
数据后站稳243.98再看；跌破10月16日低点208.92，算预期打完。
周六晚数据出来前，你会拿着 Moderna 过周末吗，拿还是不拿？
$MRNA $MRK
#Moderna #癌症疫苗
看见了：周二 Moderna 涨6.7%，盘中243.98创52周新高。
一年前最低收盘才22.36，现在翻了10倍多；8月19日三期初步结果出来，一天涨了177%。
和默沙东合作的黑色素瘤个性化疫苗，完整三期数据10月24日22:30（北京时间）在ESMO公布。
我觉得好消息大半已经在价格里，数据只要不够惊艳，就容易见光死；过去90天公司内部人还卖了约3390万美元股票。
我怎么做：不追，也不提前做空。
数据后站稳243.98再看；跌破10月16日低点208.92，算预期打完。
周六晚数据出来前，你会拿着 Moderna 过周末吗，拿还是不拿？
$MRNA $MRK
#Moderna #癌症疫苗
425
·
--
#ModernaRisesOver12%
Moderna (MRNA) shares shot up more than 12% yesterday, closing at about $67.
Why the big jump?
> The company shared exciting updates on new mRNA treatments for cancer prevention, autoimmune diseases and more.
> Good news from the FDA on their flu vaccine also helped boost confidence.
This is a big win for the biotech company, which has been working hard to expand beyond COVID vaccines. Investors are feeling optimistic about the future!
What do you think — is this the start of something bigger for Moderna?
#Moderna #Stocks #MRNA
#ModernaRisesOver12%
Moderna (MRNA) shares shot up more than 12% yesterday, closing at about $67.
Why the big jump?
> The company shared exciting updates on new mRNA treatments for cancer prevention, autoimmune diseases and more.
> Good news from the FDA on their flu vaccine also helped boost confidence.
This is a big win for the biotech company, which has been working hard to expand beyond COVID vaccines. Investors are feeling optimistic about the future!
What do you think — is this the start of something bigger for Moderna?
#Moderna #Stocks #MRNA
Moderna (MRNA) shares shot up more than 12% yesterday, closing at about $67.
Why the big jump?
> The company shared exciting updates on new mRNA treatments for cancer prevention, autoimmune diseases and more.
> Good news from the FDA on their flu vaccine also helped boost confidence.
This is a big win for the biotech company, which has been working hard to expand beyond COVID vaccines. Investors are feeling optimistic about the future!
What do you think — is this the start of something bigger for Moderna?
#Moderna #Stocks #MRNA
MRNAonAlpha
MRNAUS-5,49%
93
·
--
Жоғары (өспелі)
$MRNAB is stabilizing near support levels after a notable pull-back, showing signs of buyer defense around current prices. A successful consolidation here could ignite a relief bounce to challenge upper supply levels.
Target 1: 148.00 Target 2: 152.00 Target 3: 156.00
#MRNAB #Moderna #Crypto
$TUT
{future}(TUTUSDT)
$ZEC
{future}(ZECUSDT)
{spot}(MRNABUSDT)
$MRNAB is stabilizing near support levels after a notable pull-back, showing signs of buyer defense around current prices. A successful consolidation here could ignite a relief bounce to challenge upper supply levels.
Target 1: 148.00 Target 2: 152.00 Target 3: 156.00
#MRNAB #Moderna #Crypto
$TUT
$ZEC
Target 1: 148.00 Target 2: 152.00 Target 3: 156.00
#MRNAB #Moderna #Crypto
$TUT
$ZEC
3
381
·
--
$MRNAon has displayed a powerful initial breakout, pumping over 12% to test a high near 159.42 before encountering quick resistance. Price has since retraced on the 15m chart and is currently forming a tight, low-volatility consolidation range right around the 145.66 level. A successful defense of this base near 142.40 will be crucial for buyers to build momentum for another leg upward.
Target 1: 151.00 Target 2: 159.40 Target 3: 168.00
#MRNAon #Moderna #CryptoTrading #Altcoins
$TRUMP
{future}(TRUMPUSDT)
{alpha}(560x01486675da0764ee780ea7cb65c33062e9b2d28c)
$ZEC
{future}(ZECUSDT)
$MRNAon has displayed a powerful initial breakout, pumping over 12% to test a high near 159.42 before encountering quick resistance. Price has since retraced on the 15m chart and is currently forming a tight, low-volatility consolidation range right around the 145.66 level. A successful defense of this base near 142.40 will be crucial for buyers to build momentum for another leg upward.
Target 1: 151.00 Target 2: 159.40 Target 3: 168.00
#MRNAon #Moderna #CryptoTrading #Altcoins
$TRUMP
$ZEC
Target 1: 151.00 Target 2: 159.40 Target 3: 168.00
#MRNAon #Moderna #CryptoTrading #Altcoins
$TRUMP
$ZEC
1
242
·
--
هذا أمر مذهل. ارتفع سهم شركة "موديرنا" (Moderna) بنحو 150% اليوم، ليقفز إلى المركز الثاني ضمن قائمة الأسهم الأفضل أداءً في مؤشر "إس آند بي 500" (S&P 500) لعام 2026. وبات السهم يحتل هذا الموقع المتميز بمفرده في قائمة تهيمن عليها شركات الذكاء الاصطناعي، ولا يسبقه سوى سهم شركة "سانديسك" (Sandisk).
{stock_us}(MRNA.US)
#stocks #moderna #SNDK #S&P500
{stock_us}(DELL.US)
هذا أمر مذهل. ارتفع سهم شركة "موديرنا" (Moderna) بنحو 150% اليوم، ليقفز إلى المركز الثاني ضمن قائمة الأسهم الأفضل أداءً في مؤشر "إس آند بي 500" (S&P 500) لعام 2026. وبات السهم يحتل هذا الموقع المتميز بمفرده في قائمة تهيمن عليها شركات الذكاء الاصطناعي، ولا يسبقه سوى سهم شركة "سانديسك" (Sandisk).
#stocks #moderna #SNDK #S&P500
#stocks #moderna #SNDK #S&P500
1
105
·
--
Жоғары (өспелі)
🚨 MODERNA SURGES 14% AFTER CANCER-THERAPY BREAKTHROUGH 📈
Moderna jumped 14.36% after Moderna and Merck reported positive Phase III results for their personalized mRNA cancer therapy, intismeran autogene, in high-risk melanoma.
🏦 Major banks responded by raising Moderna’s price targets, with Bank of America moving from $40 to $170 and Piper Sandler from $77 to $167.
🎯 TRADING VIEW: BUY 📈
The strong clinical results and major target upgrades create a bullish catalyst, but traders should monitor whether momentum holds after the sharp rally.
❓ Can Moderna extend this breakout? "CLICK ON THE BELOW YELLOW COIN TAG TO GO TO DESIRED TRADING PAGE TO GET BENEFIT TRADE"$MRNA
{future}(MRNAUSDT)
#moderna #MRNAon
🚨 MODERNA SURGES 14% AFTER CANCER-THERAPY BREAKTHROUGH 📈
Moderna jumped 14.36% after Moderna and Merck reported positive Phase III results for their personalized mRNA cancer therapy, intismeran autogene, in high-risk melanoma.
🏦 Major banks responded by raising Moderna’s price targets, with Bank of America moving from $40 to $170 and Piper Sandler from $77 to $167.
🎯 TRADING VIEW: BUY 📈
The strong clinical results and major target upgrades create a bullish catalyst, but traders should monitor whether momentum holds after the sharp rally.
❓ Can Moderna extend this breakout? "CLICK ON THE BELOW YELLOW COIN TAG TO GO TO DESIRED TRADING PAGE TO GET BENEFIT TRADE"$MRNA
#moderna #MRNAon
Moderna jumped 14.36% after Moderna and Merck reported positive Phase III results for their personalized mRNA cancer therapy, intismeran autogene, in high-risk melanoma.
🏦 Major banks responded by raising Moderna’s price targets, with Bank of America moving from $40 to $170 and Piper Sandler from $77 to $167.
🎯 TRADING VIEW: BUY 📈
The strong clinical results and major target upgrades create a bullish catalyst, but traders should monitor whether momentum holds after the sharp rally.
❓ Can Moderna extend this breakout? "CLICK ON THE BELOW YELLOW COIN TAG TO GO TO DESIRED TRADING PAGE TO GET BENEFIT TRADE"$MRNA
#moderna #MRNAon
1
368
·
--
Жоғары (өспелі)
Расталды
BIO+0,96%
MRNAUS-5,49%
704
·
--
Жоғары (өспелі)
قبل ٧ ساعات فقط جلبت لكم خبر رائع سيرفع سهم شركة $MRNA.US وكان السعر حينها 120 $ , وأخبرتكم أنه سيرتفع كما هو موضح 👇 والآن وصل سعر السهم 194 $ 🔥👌🚀🚀
#stocks #MRNA #moderna #Stocks_DAB3
{stock_us}(MRNA.US)
قبل ٧ ساعات فقط جلبت لكم خبر رائع سيرفع سهم شركة $MRNA.US وكان السعر حينها 120 $ , وأخبرتكم أنه سيرتفع كما هو موضح 👇 والآن وصل سعر السهم 194 $ 🔥👌🚀🚀
#stocks #MRNA #moderna #Stocks_DAB3
#stocks #MRNA #moderna #Stocks_DAB3
DAB3_1997
·
--
Жоғары (өспелі)سهم $MRNA.US يرتفع بقوة بفضل النتائج الناجحة للقاح ضد سرطان الميلانوما. 💉
#stocks #stoksDAB3 #MRNA
#stocks #stoksDAB3 #MRNA
MRNAUS-5,49%
1
32
·
--
Жоғары (өспелі)
قفز سهم شركة "موديرنا" (MRNA) بنسبة 150% - محققاً أفضل أداء يومي في تاريخه - بعد أن أظهر لقاح للسرطان إمكانيةً في منع تكرار الإصابة بالورم الميلانيني. 📈 📈
{stock_us}(MRNA.US)
#stocks #stocksDAB3 #stockDAB3 #moderna
قفز سهم شركة "موديرنا" (MRNA) بنسبة 150% - محققاً أفضل أداء يومي في تاريخه - بعد أن أظهر لقاح للسرطان إمكانيةً في منع تكرار الإصابة بالورم الميلانيني. 📈 📈
#stocks #stocksDAB3 #stockDAB3 #moderna
#stocks #stocksDAB3 #stockDAB3 #moderna
MRNAUS-5,49%
1
44
·
--
Жоғары (өспелі)
🚨 سيتم إدراج شركة "موديرنا" (Moderna) في مؤشر "ناسداك 100" (Nasdaq 100) بعد أن سجل سهمها ارتفاعاً هائلاً تجاوز 600% في عام 2026.
لقد دفع هذا الصعود القوي شركة "موديرنا" لتصبح واحدة من أبرز الشركات المدرجة في المؤشر، مما يمثل تحولاً جذرياً في مسار الشركة هذا العام.
#stocks #BStocks #الأسهم_الأمريكية #moderna
$MRNAB
{spot}(MRNABUSDT)
🚨 سيتم إدراج شركة "موديرنا" (Moderna) في مؤشر "ناسداك 100" (Nasdaq 100) بعد أن سجل سهمها ارتفاعاً هائلاً تجاوز 600% في عام 2026.
لقد دفع هذا الصعود القوي شركة "موديرنا" لتصبح واحدة من أبرز الشركات المدرجة في المؤشر، مما يمثل تحولاً جذرياً في مسار الشركة هذا العام.
#stocks #BStocks #الأسهم_الأمريكية #moderna
$MRNAB
لقد دفع هذا الصعود القوي شركة "موديرنا" لتصبح واحدة من أبرز الشركات المدرجة في المؤشر، مما يمثل تحولاً جذرياً في مسار الشركة هذا العام.
#stocks #BStocks #الأسهم_الأمريكية #moderna
$MRNAB
1
42
·
--
Расталды
🚨 موديرنا وميرك تعلنان تقدّمًا كبيرًا في لقاح شخصي لعلاج السرطان بتقنية mRNA
في تطور لافت بمجال علاج السرطان، أعلنت شركتا Moderna وMerck عن نتائج إيجابية لتجربة المرحلة الثالثة (Phase 3) للقاح سرطان شخصي يعتمد على تقنية mRNA.
الفكرة مختلفة عن اللقاحات التقليدية:
يتم تصميم اللقاح خصيصًا لكل مريض بناءً على الطفرات الجينية الموجودة داخل الورم، بهدف مساعدة جهاز المناعة على التعرف على الخلايا السرطانية ومهاجمتها بدقة أكبر.
وبحسب الإعلان، شملت الدراسة 1,137 مريضًا بسرطان الجلد عالي الخطورة، وتم استخدام اللقاح مع دواء Keytruda التابع لشركة Merck بعد إزالة الورم جراحيًا.
📌 النتائج المعلنة أظهرت:
• انخفاض خطر عودة السرطان بشكل ملحوظ
• تقليل احتمالية انتشار المرض إلى مناطق أخرى من الجسم
وتأمل Moderna في المضي قدمًا نحو طرح العلاج تجاريًا بعد استكمال الإجراءات التنظيمية اللازمة.
📈 الخبر انعكس بقوة على أسهم الشركتين:
Merck سجلت مستويات قياسية جديدة، بينما قفز سهم Moderna بقوة ووصلت مكاسبه إلى أكثر من 180% خلال موجة الصعود الأخيرة، مع تداول السهم فوق 181 دولارًا في تعاملات ما بعد السوق وفق الأرقام المتداولة مع الخبر.
#Moderna #Merck #MRNA #Cancer #Keytruda #Stocks #Biotech
🚨 موديرنا وميرك تعلنان تقدّمًا كبيرًا في لقاح شخصي لعلاج السرطان بتقنية mRNA
في تطور لافت بمجال علاج السرطان، أعلنت شركتا Moderna وMerck عن نتائج إيجابية لتجربة المرحلة الثالثة (Phase 3) للقاح سرطان شخصي يعتمد على تقنية mRNA.
الفكرة مختلفة عن اللقاحات التقليدية:
يتم تصميم اللقاح خصيصًا لكل مريض بناءً على الطفرات الجينية الموجودة داخل الورم، بهدف مساعدة جهاز المناعة على التعرف على الخلايا السرطانية ومهاجمتها بدقة أكبر.
وبحسب الإعلان، شملت الدراسة 1,137 مريضًا بسرطان الجلد عالي الخطورة، وتم استخدام اللقاح مع دواء Keytruda التابع لشركة Merck بعد إزالة الورم جراحيًا.
📌 النتائج المعلنة أظهرت:
• انخفاض خطر عودة السرطان بشكل ملحوظ
• تقليل احتمالية انتشار المرض إلى مناطق أخرى من الجسم
وتأمل Moderna في المضي قدمًا نحو طرح العلاج تجاريًا بعد استكمال الإجراءات التنظيمية اللازمة.
📈 الخبر انعكس بقوة على أسهم الشركتين:
Merck سجلت مستويات قياسية جديدة، بينما قفز سهم Moderna بقوة ووصلت مكاسبه إلى أكثر من 180% خلال موجة الصعود الأخيرة، مع تداول السهم فوق 181 دولارًا في تعاملات ما بعد السوق وفق الأرقام المتداولة مع الخبر.
#Moderna #Merck #MRNA #Cancer #Keytruda #Stocks #Biotech
في تطور لافت بمجال علاج السرطان، أعلنت شركتا Moderna وMerck عن نتائج إيجابية لتجربة المرحلة الثالثة (Phase 3) للقاح سرطان شخصي يعتمد على تقنية mRNA.
الفكرة مختلفة عن اللقاحات التقليدية:
يتم تصميم اللقاح خصيصًا لكل مريض بناءً على الطفرات الجينية الموجودة داخل الورم، بهدف مساعدة جهاز المناعة على التعرف على الخلايا السرطانية ومهاجمتها بدقة أكبر.
وبحسب الإعلان، شملت الدراسة 1,137 مريضًا بسرطان الجلد عالي الخطورة، وتم استخدام اللقاح مع دواء Keytruda التابع لشركة Merck بعد إزالة الورم جراحيًا.
📌 النتائج المعلنة أظهرت:
• انخفاض خطر عودة السرطان بشكل ملحوظ
• تقليل احتمالية انتشار المرض إلى مناطق أخرى من الجسم
وتأمل Moderna في المضي قدمًا نحو طرح العلاج تجاريًا بعد استكمال الإجراءات التنظيمية اللازمة.
📈 الخبر انعكس بقوة على أسهم الشركتين:
Merck سجلت مستويات قياسية جديدة، بينما قفز سهم Moderna بقوة ووصلت مكاسبه إلى أكثر من 180% خلال موجة الصعود الأخيرة، مع تداول السهم فوق 181 دولارًا في تعاملات ما بعد السوق وفق الأرقام المتداولة مع الخبر.
#Moderna #Merck #MRNA #Cancer #Keytruda #Stocks #Biotech
1
590
Көбірек контент көру үшін кіріңіз
Binance Square платформасында әлемдік криптоқоғамдастыққа қосылыңыз
⚡️ Криптовалюта туралы ең соңғы және пайдалы ақпаратты алыңыз.
💬 Әлемдегі ең ірі криптобиржаның сеніміне ие.
👍 Расталған авторлардың нақты пікірлерін табыңыз.
Электрондық пошта/телефон нөмірі
Трендтегі тақырыптар
1
#HotCPIDecemberHikePriced
85,990 рет көрілді
1,018 адам талқылап жатыр
2
#TrumpMediaAdds1510BTCInQ3
203 рет көрілді
26 адам талқылап жатыр
3
#AnthropicRejectsIPODelayValuationinQuestion
212,758 рет көрілді
1,781 адам талқылап жатыр
4
#NvidiaInvestigatesAfterHuang’sAffairApology
503,369 рет көрілді
3,186 адам талқылап жатыр
5
#CanNvidiaEarningsEaseMarketConcerns?
33,152 рет көрілді
488 адам талқылап жатыр
6
#ADPWeeklyEstimateShowsUSPrivatePayrollsUp19750
15,197 рет көрілді
268 адам талқылап жатыр
7
#US-IranTalksFuelStrongStockMarketRebound
145,216 рет көрілді
618 адам талқылап жатыр
8
#BitcoinFiveWeeklyLosses
528,581 рет көрілді
3,332 адам талқылап жатыр
9
#AIChipSlumpNasdaq
279,479 рет көрілді
1,835 адам талқылап жатыр
10
#BitcoinSpotETFsPost$201MNetOutflowForThirdStraightDay
2,310 рет көрілді
34 адам талқылап жатыр